DrugPatentWatch Database Preview
Bausch And Lomb Company Profile
What is the competitive landscape for BAUSCH AND LOMB, and what generic alternatives to BAUSCH AND LOMB drugs are available?
BAUSCH AND LOMB has seventy-seven approved drugs.
There are twenty-seven US patents protecting BAUSCH AND LOMB drugs.
There are two hundred and twenty-nine patent family members on BAUSCH AND LOMB drugs in forty-two countries and fifty supplementary protection certificates in eleven countries.
Summary for Bausch And Lomb
| International Patents: | 229 |
| US Patents: | 27 |
| Tradenames: | 66 |
| Ingredients: | 54 |
| NDAs: | 77 |
| Patent Litigation for Bausch And Lomb: | See patent lawsuits for Bausch And Lomb |
Drugs and US Patents for Bausch And Lomb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | VYZULTA | latanoprostene bunod | SOLUTION/DROPS;OPHTHALMIC | 207795-001 | Nov 2, 2017 | RX | Yes | Yes | 7,273,946 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | RX | Yes | Yes | 6,780,877 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Bausch And Lomb Inc | BROMDAY | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-002 | Oct 16, 2010 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Bausch And Lomb | PROLENSA | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 203168-001 | Apr 5, 2013 | RX | Yes | Yes | 8,129,431 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Bausch And Lomb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | 5,540,930*PED | ➤ Sign Up |
| Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | 5,747,061*PED | ➤ Sign Up |
| Bausch And Lomb Inc | XIBROM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-001 | Mar 24, 2005 | 4,910,225 | ➤ Sign Up |
| Bausch And Lomb | VITRASERT | ganciclovir | IMPLANT;IMPLANTATION | 020569-001 | Mar 4, 1996 | 5,378,475 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
| ➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
Non-Orange Book US Patents for Bausch And Lomb
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,987,270 | Formulations of selective alpha-2 agonists and methods of use thereof | ➤ Sign Up |
| 7,449,469 | Prostaglandin derivatives | ➤ Sign Up |
| 9,849,121 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | ➤ Sign Up |
| 8,580,787 | Compositions and methods for reducing activation of alpha-1 receptors | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Bausch And Lomb Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1041642 | ➤ Sign Up |
| South Korea | 20080007415 | ➤ Sign Up |
| Argentina | 047081 | ➤ Sign Up |
| Australia | 2008228941 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Bausch And Lomb Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB12/058 | United Kingdom | ➤ Sign Up | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 90041 | Netherlands | ➤ Sign Up | PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306 |
| 90031-1 | Sweden | ➤ Sign Up | PRODUCT NAME: LATANOPROST |
| 00494 | Netherlands | ➤ Sign Up | PRODUCT NAME: BROMFENAC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
